

## Supplementary table 1:

**Table 1** Baseline clinical characteristics of the subjects included in this study

Baseline clinical characteristics	CONTROL (N=25)		INTESTINAL BARRIER DYSFUNCTION (N=24)		
	Healthy	Chemotherapy	IBD	Mucositis	HIV
Male/female (%)	4/8 (33.3/66.6)	0/13 (0/100)	6/7 (46.2/53.9)	0/5 (0/100)	6/0 (100/0)
Age* (min-max)	36 (24-59)	53 (43-72)	35 (25-57)	58 (49-69)	39 (26-59)
Ulcerative colitis (UC)/Crohn's disease (CD) (%)			3/10 (23.1/76.9)		
Disease activity at blood sampling: active/remission (%)			7/6 (53.9/46.2)		
Maximum disease location (Montreal classification) (CD)					
L1 ileal (%)			1 (7.7)		
L2 colonic (%)			2 (15.4)		
L3 ileocolonic (%)			6 (46.2)		
L4 isolated upper disease (%)			1 (7.7)		
Disease behaviour at blood sampling (UC)					
E1 proctitis (%)			0 (0)		
E2 left sided colitis (%)			2 (15.4)		
E3 pancolitis (%)			1 (7.7)		
Radiation-/chemotherapy-induced intestinal mucositis (%)				2/3 (40/60)	
Breast cancer (%)		10 (76.9)		3 (60)	
Ovarian cancer (%)		3 (23.1)		0 (0)	
Endometrial cancer (%)		0 (0)		2 (40)	
Viral replication (log HIV-1 RNA copies/ml)					3.04-7.00
Immune status monitoring					
CD4, cells/ $\mu$ l* (min-max)					777.5 (199-881)
CD8, cells/ $\mu$ l* (min-max)					675.5 (263-1450)
NK, cells/ $\mu$ l* (min-max)					275.0 (170-708)
CRP, mg/l* (min-max)			1.7 (<0.6-148.3)		1.25 (0.8-2.9)

\*median values